BLISS GVS PHARMA LTD
BLISSGVS · General/Diversified · NSE
₹269
Current Market Price
Fair Value (DCF)
₹144
Margin of Safety
-46.4%
Updated 12h ago
YieldIQ Score
22/100
Piotroski F-Score
5/9
Economic Moat
Moderate
Confidence
57%
ROE
—
Debt/Equity
0.04
WACC
11.1%
Market Cap
₹2,844 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
11.7%
Return on capital employed
EV / EBITDA
20.4×
Enterprise multiple
Debt / EBITDA
0.7×
Leverage vs earnings
Interest Coverage
21.3×
EBIT covers interest
Current Ratio
4.81×
Short-term liquidity
Asset Turnover
0.62×
Revenue per ₹ of assets
Revenue CAGR (3Y)
2.8%
3-year revenue growth
Revenue CAGR (5Y)
—
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹268.79
Bear case
₹86.3
MoS -211.5%
Base case
₹144.03
MoS -86.6%
Bull case
₹181.64
MoS -48.0%
Ratio Trends
BLISSGVS · last 9 annual periods
ROE
7.7%
ROCE
13.7%
Operating Margin
—
Debt / Equity
0.08×
PE
217.2×
EV / EBITDA
6.1×
Historical Financials
BLISSGVS · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹577 Cr | ₹747 Cr | ₹185 Cr | ₹198 Cr | ₹802 Cr | +8.6% |
| EBITDA | — | ₹74.4 Cr | ₹128 Cr | ₹149 Cr | ₹161 Cr | +21.3% |
| EBIT | ₹110 Cr | ₹58.9 Cr | ₹4.3 Cr | ₹-2.1 Cr | — | — |
| PAT | ₹74.0 Cr | ₹23.5 Cr | ₹3.5 Cr | ₹-4.9 Cr | ₹84.3 Cr | +3.3% |
| EPS (diluted) | ₹6.49 | ₹1.87 | ₹0.33 | ₹-0.86 | — | — |
| CFO | ₹64.0 Cr | ₹135 Cr | ₹34.3 Cr | ₹152 Cr | ₹106 Cr | +13.4% |
| CapEx | — | — | — | — | ₹-76.3 Cr | — |
| FCF | — | — | — | — | ₹29.6 Cr | +0.0% |
| Total Assets | — | ₹1109 Cr | ₹1157 Cr | ₹1214 Cr | ₹1301 Cr | +4.1% |
| Total Debt | — | — | ₹57.4 Cr | ₹52.2 Cr | ₹88.1 Cr | +11.3% |
| Shareholders' Equity | — | — | ₹884 Cr | ₹967 Cr | ₹1092 Cr | +5.4% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
BLISSGVS vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
| IOLCP IOLCP | — | — | Pending | 6.0% | — |
| ORCHPHARMA ORCHID PHARMA LIMITED | -28.8% | 29 | Overvalued | 7.9% | — |
| GUFICBIO GUFICBIO | — | — | Pending | 11.6% | — |
| UNICHEMLAB UNICHEMLAB | — | — | Pending | 5.6% | — |
| SOLARA SOLARA | — | — | Pending | 0.0% | — |
Click a ticker to view its fair-value analysis.
Dividend History
No dividend events recorded for BLISSGVS in the last 10 years.
AI Analysis Summary
Model-generated description of metrics. Not investment advice. BLISSGVS.NS has a current price of 268.79 and fair value of 144.03, with ROCE of 11.7% and debt-to-equity of 0.04. Its revenue CAGR is 2....
Read full AI analysis →Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of BLISSGVS →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for BLISSGVS →
Compare
Head-to-head with peers
Compare BLISSGVS side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse BLISSGVSNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.